Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

Conditions

Chronic Kidney Disease

Brief summary

Percentage change from baseline to week 32/36 in first morning void UACR

Detailed description

Change from baseline to week 36 in eGFR (creatinine, cystatin C, and creatinine-cystatin C), Change from baseline to week 36 in Iohexol measured GFR (subset of 60 participants), Change in UACR and eGFR during 4-week wash-out from week 36 to 40, Change from baseline to week 36 in Perirenal and renal sinus fat measured by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Subcutaneous and visceral fat assessed by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Body weight, Change from baseline to week 36 in Waist circumference, Change from baseline to week 36 in Systolic and diastolic blood pressure

Related papers

No related papers found yet.

Papers published before 2002-11-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGBI 456906

DRUGMatching placebo for Survodutide

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage change from baseline to week 32/36 in first morning void UACR	—

Secondary

Measure	Time frame
Change from baseline to week 36 in eGFR (creatinine, cystatin C, and creatinine-cystatin C), Change from baseline to week 36 in Iohexol measured GFR (subset of 60 participants), Change in UACR and eGFR during 4-week wash-out from week 36 to 40, Change from baseline to week 36 in Perirenal and renal sinus fat measured by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Subcutaneous and visceral fat assessed by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Body weight, Change from baseline to week 36 in Waist circumference, Change from baseline to week 36 in Systolic and diastolic blood pressure	—

Measure

Time frame

Change from baseline to week 36 in eGFR (creatinine, cystatin C, and creatinine-cystatin C), Change from baseline to week 36 in Iohexol measured GFR (subset of 60 participants), Change in UACR and eGFR during 4-week wash-out from week 36 to 40, Change from baseline to week 36 in Perirenal and renal sinus fat measured by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Subcutaneous and visceral fat assessed by MRI (same subset of 60 participants with Iohexol GFR), Change from baseline to week 36 in Body weight, Change from baseline to week 36 in Waist circumference, Change from baseline to week 36 in Systolic and diastolic blood pressure

—

Outcome results

None listed